Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announces its intended acquisition of Certara’s Regulatory and Medical Writing business. The team that will join Veristat is known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The acquisition is supported by WindRose Health Investors, LLC, a New York-based healthcare private equity firm, which remains a partner in driving Veristat’s growth trajectory and mission.
Read the full article: Veristat to Acquire Certara’s Regulatory and Medical Writing Business //
Source: https://www.businesswire.com/news/home/20260422264798/en/Veristat-to-Acquire-Certaras-Regulatory-and-Medical-Writing-Business